AIA
CRL icon

Arcadia Investment Advisors’s Charles River Laboratories CRL Stock Holding History

Arcadia Investment Advisors’s Portfolio CRL Stock Details CRL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-2
Closed -$740 – 137
2021
Q2 		$740 Buy
+2
New +$668 ﹤0.01% 196

Other funds holding CRL

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Kayne Anderson Rudnick Investment Management
Kayne Anderson Rudnick Investment Management Los Angeles, California $34B AUM 6.31% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
Massachusetts Financial Services
Massachusetts Financial Services Boston, Massachusetts $298B AUM 21.96% 1-Year Est. Return
William Blair Investment Management
William Blair Investment Management Chicago, Illinois $30.3B AUM 33.75% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Royal Bank of Canada
Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return

Arcadia Investment Advisors's CRL Position: Q3 2021 in Review

Arcadia Investment Advisors sold out of Charles River Laboratories (CRL) in Q3 2021, closing a stake of 2 shares — an estimated $740 sold.

Arcadia Investment Advisors first reported a position in CRL in Q2 2021 and held it in 1 quarter. The position peaked at $740 in Q2 2021. 676 funds tracked by Wall St. Rank hold CRL as of Q3 2021.

  • Arcadia Investment Advisors reported no remaining Charles River Laboratories position as of Q3 2021 after selling out during the quarter.
  • Arcadia Investment Advisors sold 2 Charles River Laboratories shares in Q3 2021, an estimated $740.
  • Arcadia Investment Advisors first reported a position in Charles River Laboratories in Q2 2021 and held it in 1 quarter.
  • Arcadia Investment Advisors's Charles River Laboratories position peaked at $740 in Q2 2021.
  • 676 funds tracked by Wall St. Rank held Charles River Laboratories as of Q3 2021.

Based on Arcadia Investment Advisors's 13F filing for Q3 2021, filed 19 Dec 2024.